Open AccessSerum TFF1 and TFF3 but not TFF2 are higher in women with breast cancer than in women without breast cancer
Author(s) -
Yuko Ishibashi,
Hiroshi Ohtsu,
Masako Ikemura,
Yasuko Kikuchi,
Tetsu Niwa,
Koki Nishioka,
Yoshihiro Uchida,
Hirona Miura,
Susumu Aikou,
Toshiaki Gunji,
Nobuyuki Matsuhashi,
Yasukazu Ohmoto,
Takeshi Sasaki,
Yasuyuki Seto,
Toshihisa Ogawa,
Keiichiro Tada,
Sachiyo Nomura
Publication year - 2017
Publication title -
scientific reports
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.24
H-Index - 213
ISSN - 2045-2322
DOI - 10.1038/s41598-017-05129-y
Subject(s) - breast cancer , cancer , medicine , oncology , gynecology , physiology
Breast cancer remains a common malignancy in women, but the take-up for breast cancer screening programs in Japan is still low, possibly due to its perceived inconvenience. TFF1 and TFF3 are expressed in both breast cancer tissue and normal breast. Serum trefoil proteins were reported as cancer screening markers for gastric, prostate, lung, pancreatic cancer and cholangio carcinoma. The purpose of this study was to examine whether serum trefoil proteins could be screening biomarkers for breast cancer. Serum trefoil proteins in 94 breast cancer patients and 84 health check females were measured by ELISA. Serum TFF1 and TFF3 were significantly higher and serum TFF2 was significantly lower in breast cancer patients. Area under the curve of receiver operating characteristic of TFF1, TFF2, and TFF3 was 0.69, 0.83, and. 0.72, respectively. AUC of the combination of TFF1, TFF2, and TFF3 was 0.96. Immunohistochemically, TFF1 expression was positive in 56.5% and TFF3 was positive in 73.9% of breast cancers, while TFF2 was negative in all tumors. Serum TFF1 had positive correlation with expression of TFF1 in breast cancer tissue. Serum concentrations of TFF1 and TFF3 but not TFF2 are higher in women with breast cancer than in women without breast cancer.